Wellington Management Group
HRTX icon

Wellington Management Group’s Heron Therapeutics HRTX Stock Holding History

Wellington Management Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-525,774
Closed -$662K – 1991
2025
Q3 		$662K Buy
525,774
+32,691
+7% +$51.8K ﹤0.01% 1850
2025
Q2 		$1.02M Buy
493,083
+5,841
+1% +$11.9K ﹤0.01% 1718
2025
Q1 		$1.07M Sell
487,242
-880
-0.2% -$1.71K ﹤0.01% 1691
2024
Q4 		$747K Sell
488,122
-8,105
-2% -$13.1K ﹤0.01% 1776
2024
Q3 		$987K Sell
496,227
-24,967
-5% -$59.6K ﹤0.01% 1712
2024
Q2 		$1.82M Buy
521,194
+103,209
+25% +$317K ﹤0.01% 1543
2024
Q1 		$1.16M Buy
+417,985
New +$1.05M ﹤0.01% 1654
2023
Q2 		– Sell
-312,286
Closed -$472K – 1891
2023
Q1 		$472K Sell
312,286
-14,368
-4% -$36K ﹤0.01% 1847
2022
Q4 		$817K Sell
326,654
-6,257
-2% -$20.2K ﹤0.01% 1685
2022
Q3 		$1.41M Sell
332,911
-90,682
-21% -$355K ﹤0.01% 1592
2022
Q2 		$1.18M Sell
423,593
-1,306,179
-76% -$5.24M ﹤0.01% 1648
2022
Q1 		$9.89M Buy
1,729,772
+91,499
+6% +$670K ﹤0.01% 1200
2021
Q4 		$15M Sell
1,638,273
-784,149
-32% -$8.01M ﹤0.01% 1146
2021
Q3 		$25.9M Sell
2,422,422
-1,799,267
-43% -$21.9M ﹤0.01% 1014
2021
Q2 		$65.5M Sell
4,221,689
-1,625,659
-28% -$25.9M 0.01% 744
2021
Q1 		$94.8M Sell
5,847,348
-1,088,566
-16% -$19.4M 0.02% 623
2020
Q4 		$147M Buy
6,935,914
+3,322,618
+92% +$57.7M 0.03% 486
2020
Q3 		$53.5M Buy
3,613,296
+488,201
+16% +$7.62M 0.01% 678
2020
Q2 		$46M Buy
3,125,095
+685,099
+28% +$11.3M 0.01% 720
2020
Q1 		$28.6M Sell
2,439,996
-2,057,833
-46% -$38.7M 0.01% 783
2019
Q4 		$106M Buy
4,497,829
+108,312
+2% +$2.4M 0.02% 551
2019
Q3 		$81.2M Sell
4,389,517
-408,221
-9% -$7.51M 0.02% 597
2019
Q2 		$89.2M Sell
4,797,738
-347,250
-7% -$6.94M 0.02% 595
2019
Q1 		$126M Buy
5,144,988
+567,117
+12% +$14.8M 0.03% 496
2018
Q4 		$119M Sell
4,577,871
-35,446
-0.8% -$975K 0.03% 454
2018
Q3 		$146M Sell
4,613,317
-156,858
-3% -$5.84M 0.03% 465
2018
Q2 		$185M Buy
4,770,175
+2,597,229
+120% +$82.7M 0.04% 397
2018
Q1 		$60M Buy
+2,172,946
New +$49.3M 0.01% 724

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Wellington Management Group's HRTX Position: Q4 2025 in Review

Wellington Management Group sold out of Heron Therapeutics (HRTX) in Q4 2025, closing a stake of 525,774 shares — an estimated $662K sold.

Wellington Management Group first reported a position in HRTX in Q1 2018 and held it in 28 quarters. The position peaked at $185M in Q2 2018. 170 funds tracked by Wall St. Rank hold HRTX as of Q4 2025.

  • Wellington Management Group reported no remaining Heron Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wellington Management Group sold 525,774 Heron Therapeutics shares in Q4 2025, an estimated $662K.
  • Wellington Management Group first reported a position in Heron Therapeutics in Q1 2018 and held it in 28 quarters.
  • Wellington Management Group's Heron Therapeutics position peaked at $185M in Q2 2018.
  • 170 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2025.

Based on Wellington Management Group's 13F filing for Q4 2025, filed 17 Feb 2026.